Xavier Quantin

10.9k total citations
115 papers, 1.9k citations indexed

About

Xavier Quantin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Xavier Quantin has authored 115 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Oncology, 65 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in Xavier Quantin's work include Lung Cancer Treatments and Mutations (52 papers), Lung Cancer Research Studies (28 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Xavier Quantin is often cited by papers focused on Lung Cancer Treatments and Mutations (52 papers), Lung Cancer Research Studies (28 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Xavier Quantin collaborates with scholars based in France, United States and South Korea. Xavier Quantin's co-authors include Jean-Louis Pujol, Jean Grenier, Jean‐Marie Boher, Isabelle Solassol, Jean Louis Pujol, Frédéric Pinguet, L. Reyftmann, H. Déchaud, C. Dechanet and S. Hamamah and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Xavier Quantin

97 papers receiving 1.8k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Xavier Quantin	981	766	394	247	234	115	1.9k
Thomas Cerny	921 0.9×	477 0.6×	568 1.4×	168 0.7×	233 1.0×	53	2.2k
Adnan Aydıner	1.0k 1.0×	473 0.6×	304 0.8×	276 1.1×	295 1.3×	156	2.3k
Geert H. Blijham	989 1.0×	523 0.7×	372 0.9×	209 0.8×	227 1.0×	48	2.1k
David Goldstein	1.5k 1.5×	464 0.6×	234 0.6×	128 0.5×	269 1.1×	60	2.2k
Matthew Burnell	1.1k 1.1×	500 0.7×	637 1.6×	278 1.1×	260 1.1×	66	3.3k
Charles C. Williams	1.0k 1.0×	925 1.2×	662 1.7×	282 1.1×	201 0.9×	83	2.1k
Mark S. Walker	855 0.9×	572 0.7×	462 1.2×	107 0.4×	193 0.8×	121	2.1k
Nobuhiko Seki	812 0.8×	525 0.7×	374 0.9×	290 1.2×	97 0.4×	112	1.7k
April Coan	1.3k 1.3×	655 0.9×	434 1.1×	228 0.9×	258 1.1×	38	3.0k
Masaru Narabayashi	1.0k 1.0×	881 1.2×	338 0.9×	70 0.3×	177 0.8×	96	2.6k

Countries citing papers authored by Xavier Quantin

Since Specialization

Citations

This map shows the geographic impact of Xavier Quantin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Quantin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Quantin more than expected).

Fields of papers citing papers by Xavier Quantin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xavier Quantin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Quantin. The network helps show where Xavier Quantin may publish in the future.

Co-authorship network of co-authors of Xavier Quantin

This figure shows the co-authorship network connecting the top 25 collaborators of Xavier Quantin. A scholar is included among the top collaborators of Xavier Quantin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xavier Quantin. Xavier Quantin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chouaïd, C., D. Debieuvre, Clarisse Audigier-Valette, et al.. (2025). Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis. Frontiers in Oncology. 15. 1526931–1526931. 1 indexed citations

Gobbini, Élisa, Mamadou Diallo, Dominique Pasquier, et al.. (2025). Clinical characteristics and management of long survivors in extensive stage small cell lung cancer. Lung Cancer. 202. 108499–108499.

Faure, Stéphanie, Marie Dupuy, Dominique Larrey, et al.. (2024). Time to use the right classification to predict the severity of checkpoint inhibitor‐induced liver injury, as assessed for causality using the updated RUCAM. Alimentary Pharmacology & Therapeutics. 60(11-12). 1561–1572. 6 indexed citations

Quantin, Xavier, Pablo Lemercier, C. Chouaïd, et al.. (2024). Clinical characteristic and survival outcomes of patients with advanced NSCLC according to KRAS mutational status in the French real-life ESME cohort. ESMO Open. 9(6). 103473–103473. 4 indexed citations

Mollévi, Caroline, M. Charissoux, Amélie Darlix, et al.. (2024). Prognostic impact of the number and total tumor burden of secondary cerebral lesions in patients with resected brain metastases of non–small cell lung cancers. Journal of neurosurgery. 141(1). 89–99. 4 indexed citations

Audigier-Valette, Clarisse, Thomas Filleron, D. Debieuvre, et al.. (2023). Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy. Respiratory Medicine and Research. 84. 101012–101012. 5 indexed citations

Flaudias, Valentin, Corentin Gonthier, Marie Picot, et al.. (2023). Neuropsychological assessment fails to predict relapse among cigarette smokers: A prospective study of neurocognitive abilities. Addictive Behaviors. 151. 107940–107940. 1 indexed citations

Heudel, Pierre-Étienne, Anne Montfort, D. Debieuvre, et al.. (2023). Reduced risk of secondary primary extra pulmonary cancer in advanced/metastatic lung cancer patients treated with immune checkpoint inhibitors. Lung Cancer. 182. 107280–107280.

Lebossé, Fanny, Xavier Quantin, C. Lesage, et al.. (2023). Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Reports. 5(6). 100719–100719. 43 indexed citations

10.

Meunier, Lucy, et al.. (2023). Cholangitis Induced by Immune Checkpoint Inhibitors: Analysis of Pharmacovigilance Data. Clinical Gastroenterology and Hepatology. 22(7). 1542–1545.e4. 12 indexed citations

11.

Eslami‐S, Zahra, Luis Enrique Cortés‐Hernández, Valentin Vautrot, et al.. (2023). Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer. British Journal of Cancer. 130(1). 63–72. 30 indexed citations

12.

Léna, H., J. Cadranel, Nicolas Girard, et al.. (2023). 1404P Clinical characteristics and therapeutics sequences of KRAS G12C metastatic non-small cell lung cancer (mNCSLC) patients treated by sotorasib in the French pre-marketing authorization (MA) early access program (cohort temporary authorization of use, cATU). Annals of Oncology. 34. S803–S804. 1 indexed citations

13.

Quantin, Xavier, Jean‐Luc Faillie, C. Lesage, et al.. (2021). Gestion des toxicités induites par les inhibiteurs de checkpoint immunologique : données de la réunion de concertation pluridisciplinaire « ToxImmun » en Occitanie Est. La Revue de Médecine Interne. 42(5). 310–319. 4 indexed citations

14.

Jabbour, Salma K., Baerin Houghton, Andrew Robinson, et al.. (2020). Phase 3, Randomized, Placebo-Controlled Study of Stereotactic Body Radiotherapy (SBRT) with or Without Pembrolizumab in Patients with Inoperable Stage I/IIA Non–Small-Cell Lung Cancer (NSCLC): KEYNOTE-867. International Journal of Radiation Oncology*Biology*Physics. 108(3). e135–e136.

15.

Vendrell, Julie A., Julien Mazières, Isabelle Rouquette, et al.. (2019). Ultra-sensitive EGFR T790M Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring EGFR del19 Mutations and Treated with First-generation TKIs. Clinical Cancer Research. 25(14). 4280–4289. 28 indexed citations

16.

Bernard, Paquito, Grégory Ninot, Fabienne Cyprien, et al.. (2015). Exercise and Counseling for Smoking Cessation in Smokers With Depressive Symptoms: A Randomized Controlled Pilot Trial. Journal of Dual Diagnosis. 11(3-4). 205–216. 33 indexed citations

17.

Salaün, Mathieu, C. Chouaïd, V. Gounant, et al.. (2013). Cost-effectiveness of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for the preoperative staging of lung cancer, results from the French prospective multicenter trial "EVIEPEB". European Respiratory Journal. 42(Suppl 57). 1997–1997.

18.

Bernard, Paquito, Grégory Ninot, Sébastien Guillaume, et al.. (2012). Physical Activity as a Protective Factor in Relapse Following Smoking Cessation in Participants with a Depressive Disorder. American Journal on Addictions. 21(4). 348–355. 14 indexed citations

19.

Fond, Guillaume, Sébastien Guillaume, Sylvaine Artéro, et al.. (2012). Self-reported major depressive symptoms at baseline impact abstinence prognosis in smoking cessation program. A one-year prospective study. Journal of Affective Disorders. 149(1-3). 418–421. 19 indexed citations

20.

Pujol, Jean-Louis, Jean‐Christophe Grenier, Éric Parrat, et al.. (1996). Cytokeratins as Serum Markers in Lung Cancer: A Comparison of CYFRA 21-1 and TPS. American Journal of Respiratory and Critical Care Medicine. 154(3). 725–733. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact